MEA Point-of-Care Diagnostics Market Size, Share, and Growth Forecast 2026 - 2033

The MEA point-of-care diagnostics market size is expected to be valued at US$2.6 billion in 2026 and projected to reach US$5.8 billion by 2033, growing at a CAGR of 12.3% between 2026 and 2033, driven by the rising burden of infectious diseases across the Middle East & Africa, combined with expanding healthcare infrastructure investment.

The World Health Organization's Regional Office for the Eastern Mediterranean continues to report significant tuberculosis and hepatitis burden across the region, while Africa CDC's ongoing disease surveillance initiatives are expanding decentralized testing capacity. Growing government investment in healthcare modernization across GCC nations further accelerates point-of-care testing adoption across hospitals, clinics, and increasingly, home care settings.

Drivers - Rising Burden of Infectious Diseases Across the Region

The substantial burden of infectious diseases across the Middle East & Africa remains the foremost driver of point-of-care diagnostics adoption. The World Health Organization's Regional Office for the Eastern Mediterranean reports that the region continues to carry a disproportionate share of global tuberculosis and hepatitis C cases. Africa CDC further highlights that the African continent accounts for a substantial proportion of global malaria cases annually, necessitating rapid, decentralized diagnostic capacity across remote and underserved areas.

UNAIDS continues to identify Sub-Saharan Africa as bearing a significant share of the global HIV burden, reinforcing sustained demand for rapid infectious disease testing platforms. This considerable disease burden, combined with limited centralized laboratory infrastructure across rural regions, continues to drive strong government and donor-funded investment in point-of-care testing networks.

Expanding Healthcare Infrastructure Investment across GCC Nations

Substantial healthcare infrastructure investment across Gulf Cooperation Council nations continues to reinforce market expansion. Saudi Arabia's Vision 2030 healthcare transformation program continues to expand diagnostic capacity across public and private hospitals, while the UAE's Ministry of Health and Prevention continues to modernize primary care testing infrastructure nationwide.

The Saudi Food and Drug Authority's streamlined device registration pathways have accelerated market entry for advanced point-of-care diagnostic platforms. Growing private healthcare investment across the region, combined with rising medical tourism inflows into GCC nations, continues to expand demand for rapid, accurate diagnostic testing solutions. Companies including F. Hoffmann-La Roche Ltd and Abbott continue to expand regional distribution partnerships, further strengthening point-of-care diagnostic accessibility across the Gulf region.

Restraints - Limited Healthcare Infrastructure and Diagnostic Access in Rural Areas

Uneven healthcare infrastructure across the broader Middle East and Africa region continues to restrain consistent point-of-care diagnostics adoption. The World Health Organization's Regional Office for Africa notes that rural and remote communities across Sub-Saharan Africa often lack reliable access to basic diagnostic testing, cold-chain logistics, and trained healthcare personnel. This infrastructure gap disproportionately affects Northern Africa and the Rest of MEA regions compared to more developed GCC healthcare systems. Limited last-mile distribution networks and inconsistent electricity access in remote regions further constrain deployment of advanced diagnostic devices, slowing overall market penetration beyond urban healthcare centers.

High Import Dependency and Currency Volatility

Heavy reliance on imported diagnostic devices and reagents continues to constrain market stability across several MEA economies. Limited local manufacturing capacity for advanced point-of-care diagnostic components forces most countries to depend on imports from Europe, the United States, and Asia. The World Bank has repeatedly highlighted currency volatility across several African economies as a significant barrier to consistent healthcare procurement budgeting. These import dependencies and foreign exchange fluctuations increase device costs and create supply chain unpredictability, particularly across Northern Africa and Rest of MEA markets with less diversified healthcare financing structures.

Opportunities - Rising Demand for Rapid Cancer Marker Testing Across the Region

Growing cancer prevalence across the Middle East and Africa presents a significant opportunity for point-of-care diagnostics manufacturers. Tumor/Cancer Marker Testing, projected as the fastest-growing product segment through the forecast period, is gaining traction as governments expand early cancer detection initiatives. The World Health Organization's Regional Office for the Eastern Mediterranean has identified rising cancer incidence as an emerging public health priority across GCC and North African nations.

Companies including QIAGEN and Danaher Corporation are expanding molecular diagnostic platforms tailored for regional deployment, offering faster turnaround times compared to centralized laboratory testing. As national cancer screening programs continue expanding across Saudi Arabia, the UAE, and Egypt, demand for accessible, rapid tumor marker testing solutions is expected to accelerate significantly through 2033, creating substantial opportunity for market participants investing in regional distribution and local regulatory approvals.

Expansion of Home Care Testing and OTC Diagnostic Adoption

The growing shift toward home-based and self-administered diagnostic testing presents considerable opportunity for market participants. Rising consumer comfort with self-testing, accelerated by expanding pharmacy retail networks across GCC nations, is increasing demand for over-the-counter glucose monitoring and pregnancy testing devices. Companies including Trividia Health, Inc. and Nova Biomedical continue to expand user-friendly, minimally invasive home testing device portfolios suited for regional consumer preferences.

Growing government initiatives promoting chronic disease self-management, particularly for diabetes given the region's substantial diabetic population as tracked by the International Diabetes Federation, continue to support home care testing adoption. As digital health platforms and telehealth consultations expand across the region, integration of connected home diagnostic devices is expected to unlock substantial new demand through the forecast period.

Product Insights

Infectious disease testing is expected to dominate the product category, commanding an estimated 31% share of the market in 2026. The region's substantial burden of tuberculosis, HIV, hepatitis, and malaria continues to necessitate rapid, decentralized diagnostic capacity across hospitals, clinics, and remote community health posts.

The World Health Organization's Regional Office for the Eastern Mediterranean and Africa CDC continue to support expanded infectious disease surveillance programs, reinforcing sustained demand for rapid antigen and molecular testing platforms. Companies including BIOMÉRIEUX and F. Hoffmann-La Roche Ltd continue to expand regionally-tailored rapid diagnostic test portfolios, further consolidating this segment's decisive leadership over glucose monitoring, cardiometabolic, and other testing categories within the overall point-of-care diagnostics landscape.

Prescription Mode Analysis

Prescription-based testing is forecast to lead the prescription mode category, accounting for approximately 65% of the market in 2026. Prescription-based point-of-care diagnostics remain dominant due to the region's continued reliance on physician-supervised testing for infectious disease confirmation, cardiometabolic risk assessment, and cancer marker screening.

Regulatory frameworks across GCC nations, including the Saudi Food and Drug Authority's device classification standards, continue to mandate physician oversight for several diagnostic categories. Established hospital and clinic-based procurement relationships with manufacturers such as Siemens Healthcare Private Limited further reinforce this segment's continued dominance over the smaller but rapidly expanding OTC testing category across the region.

End-user Insights

Hospitals are likely to represent the leading end-user segment, capturing around 40% share of the market in 2026. Hospitals remain the primary diagnostic testing setting across the Middle East and Africa due to their comprehensive laboratory infrastructure, availability of specialist clinicians, and capacity to manage complex diagnostic workflows requiring immediate clinical intervention.

Government-led hospital modernization programs across Saudi Arabia, the UAE, and South Africa continue to expand point-of-care testing device deployment within emergency and inpatient care settings. Additionally, established relationships between hospitals and diagnostic manufacturers such as Abbott and BD (Becton Dickinson) ensure consistent access to advanced testing platforms, further reinforcing this segment's central role within the region's overall diagnostic care continuum.

GCC Countries Point-of-Care Diagnostics Market Trends

GCC Countries are projected to hold 39% of the MEA point-of-care diagnostics market in 2026, supported by advanced healthcare infrastructure, high healthcare expenditure, expanding diagnostic laboratories, and sustained government investment in healthcare modernization. Favorable regulatory frameworks, digital health initiatives, and increasing adoption of rapid diagnostic technologies continue reinforcing regional market leadership across major healthcare facilities.

Healthcare providers are strengthening decentralized diagnostic capabilities through expanding primary care networks, integrated digital healthcare platforms, and wider deployment of portable testing systems. Rising private sector participation, continuous investment in laboratory automation, and increasing utilization of rapid diagnostic solutions are sustaining long-term demand across the regional healthcare ecosystem.

UAE Point-of-Care Diagnostics Market Size

The UAE is projected to account for 31% of the GCC market in 2026, supported by advanced hospital infrastructure, strong government healthcare investment, and extensive adoption of innovative diagnostic technologies. Expanding medical tourism and well-established private healthcare networks continue to strengthen demand for point-of-care diagnostic solutions across the country.

National digital health initiatives, favorable regulatory support, and increasing deployment of rapid testing platforms across hospitals and outpatient centers reinforce market expansion. Growing investment in precision medicine, rising preventive healthcare awareness, and continuous modernization of healthcare facilities further strengthen the UAE's position within the regional market.

Northern Africa Point-of-Care Diagnostics Market Trends

Northern Africa is emerging as a dynamic market for point-of-care diagnostics, supported by expanding healthcare infrastructure, increasing public health expenditure, and rising demand for rapid disease detection. Governments are prioritizing decentralized diagnostic services, while growing awareness of chronic and infectious diseases is encouraging broader adoption of portable testing technologies across healthcare facilities.

Healthcare systems are benefiting from expanding primary care networks, increasing investments in laboratory capacity, and stronger collaboration between public and private healthcare providers. Rising screening initiatives for infectious diseases, greater access to diagnostic technologies, and continuous improvements in healthcare accessibility are creating favorable conditions for sustained market development.

The MEA point-of-care diagnostics market exhibits a moderately fragmented structure, with global diagnostic leaders operating alongside emerging regional manufacturers addressing localized healthcare needs. Leading companies including QIAGEN, Danaher Corporation, and F. Hoffmann-La Roche Ltd continue to expand regional distribution networks, local manufacturing partnerships, and regulatory registration pathways across GCC and African markets.

Market participants are increasingly differentiating through portable, ruggedized device designs suited for resource-limited settings, alongside expanding local training and technical support programs. Emerging business model trends include donor-funded public health partnerships and regional distribution agreements with local diagnostic companies such as Medical Diagnostech and CapeBio Technologies, expanding market accessibility across underserved communities.

Key Industry Developments:

• In April 2026, QuidelOrtho Corporation completed the acquisition of LEX Diagnostics, expanding its molecular diagnostics portfolio following FDA 510(k) clearance and CLIA waiver for the LEX VELO™ System. The acquisition strengthens QuidelOrtho's point-of-care molecular testing capabilities by adding an ultra-fast RT-PCR platform capable of delivering Influenza A/B and SARS-CoV-2 results in as little as 6–10 minutes, supporting integrated diagnostic solutions across hospitals, laboratories, and decentralized care settings.
• In March 2026, on World TB Day, the World Health Organization (WHO) called on countries to strengthen efforts to eliminate tuberculosis (TB) by expanding access to lifesaving diagnostic services. The organization emphasized the adoption of innovative technologies, including near point-of-care diagnostic tests and tongue swab-based testing, to enable faster disease detection and improve access to diagnosis for a larger population.
• In September 2024, amplifAI health, based in Riyadh, joined hands with USATherm, a leading player in point-of-care thermal imaging technology. This partnership aims to blend the expertise of both firms to set new standards in disease monitoring and diagnostic capabilities.